(MENAFN- IMARC Group)
IMARC Group's report titled“ United States Biosimilar market Report by Molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab, Pegfilgrastim, Trastuzumab, Bevacizumab, and Others), manufacturing Type (In-House Manufacturing, Contract Manufacturing), Indication (Auto-Immune Diseases, Blood Disorder, Diabetes, Oncology, Growth Deficiency, Female Infertility, and Others), and Region 2024-2032 United States Biosimilar Market Report by Molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab, Pegfilgrastim, Trastuzumab, Bevacizumab, and Others), Manufacturing Type (In-House Manufacturing, Contract Manufacturing), Indication (Auto-Immune Diseases, Blood Disorder, Diabetes, Oncology, Growth Deficiency, Female Infertility, and Others), and Region 2024-2032 ” The United States biosimilar market size is projected to exhibit a growth rate (CAGR) of 19.3% during
2024-2032.
The United States biosimilar market within the pharmaceutical industry is witnessing significant growth primarily driven by an increasing number of biosimilar products that receive FDA approval. Moreover, the increasing demand for biosimilars which are generic versions of biologic drugs, offering a cost-effective alternative to expensive brand-name biologics, making essential medications more accessible to patients, is stimulating the market growth. Additionally, the rising healthcare costs and the need to provide more affordable treatment options, along with the imminent patent expirations of several blockbuster biologics are acting as other significant growth-inducing factors. Furthermore, the ongoing supportive regulatory structure of the U.S. government is creating a positive outlook for the market.
Grab a sample PDF of this report: https://www.imarcgroup.com/united-states-biosimilar-market/requestsample
United States Biosimilar Market Trends and Drivers:
Additionally, the acceptance of the Biologics Price Competition and Innovation Act (BPCIA) which is part of the Affordable Care Act, establishing a streamlined pathway for biosimilar approval and encouraging more pharmaceutical companies to enter this space, is augmenting the market. Moreover, the rising competition and pricing strategies employed by manufacturers are acting as other significant growth-inducing factors. As biosimilars provide cost savings, the extent of the discount relative to the reference biologic varies, and market adoption can be impacted by various
factors such as payer reimbursement rules, physician and patient acceptance, and marketing strategies. Additionally, the rising commercialization and approval of biosimilars, as they play an important role in controlling healthcare costs and increasing patient access to vital treatments, particularly for chronic conditions like cancer, autoimmune diseases, and diabetes, is also contributing to the market growth. Moreover, the ongoing education and awareness initiatives aimed at healthcare providers and patients, further driving the acceptance and adoption of biosimilars, are anticipated to drive the United States biosimilar market in the coming years.
Report Segmentation:
The report has segmented the market into the following categories:
Molecule Insights:
Infliximab Insulin Glargine Epoetin Alfa Etanercept Filgrastim Somatropin Rituximab Follitropin Alfa Adalimumab Pegfilgrastim Trastuzumab Bevacizumab Others
Manufacturing Type Insights:
In-house Manufacturing Contract Manufacturing
Indication Insights:
Auto-Immune Diseases Blood Disorder Diabetes Oncology Growth Deficiency Female Infertility Others
Regional Insights:
Northeast Midwest South West
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email:
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
MENAFN01032024004122016232ID1107920695
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.